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Abstract
Background—Chronic kidney disease is associated with cardiovascular disease. We tested for
evidence of a shared genetic basis to these traits.
Study Design—We conducted two targeted analyses. First, we examined whether known single
nucleotide polymorphisms (SNPs) underpinning kidney traits were associated with a series of
vascular phenotypes. Additionally, we tested whether vascular SNPs were associated with markers
of kidney damage. Significance was set to 1.5 × 10-4 (0.05/325 tests).
Setting & Participants—Vascular outcomes were analyzed in participants from the AortaGen
(20,634), CARDIoGRAM (86,995), CHARGE Eye (15,358), CHARGE IMT (31,181), ICBP
(69,395) and NeuroCHARGE (12,385) consortia. Tests for kidney outcomes were conducted in up
to 67,093 participants from the CKDGen consortium.
Predictor—We used 19 kidney SNPs and 64 vascular SNPs.
Outcomes & Measurements—Vascular outcomes tested were blood pressure, coronary artery
disease, carotid intima-media thickness, pulse wave velocity, retinal venular caliber and brain
white matter lesions. Kidney outcomes were estimated glomerular filtration rate and albuminuria.
Results—In general, we found that kidney disease variants were not associated with vascular
phenotypes (127 of 133 tests were non-significant). The one exception was rs653178 near SH2B3
(SH2B adaptor protein 3), which showed direction-consistent association with systolic
(p=9.3E-10) and diastolic (p=1.6E-14) blood pressure and coronary artery disease (p=2.2E-6), all
previously reported. Similarly, the 64 SNPs associated with vascular phenotypes were not
associated with kidney phenotypes (187 of 192 tests were non-significant), with the exception of 2
high-correlated SNPs at the SH2B3 locus (p=1.06E-07 and p=7.05E-08).
Limitations—Combined effect size of the SNPs for kidney and vascular outcomes may be too
low to detect shared genetic associations.
Conclusions—Overall, although we confirmed one locus (SH2B3) as associated with both
kidney and cardiovascular disease, our primary findings suggest that there is little overlap between
kidney and cardiovascular disease risk variants in the overall population. The reciprocal risks of
kidney and cardiovascular disease may not be genetically mediated, but rather a function of the
disease milieu itself.
Chronic kidney disease (CKD), expressed by decreased estimated glomerular filtration rate
(eGFR) and/or the presence of albuminuria, is a major health issue, affecting almost 18
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million adults in the United States.1;2 CKD is associated with a range of serious adverse
outcomes, including end-stage renal disease and death.3 However, the major complication of
CKD is cardiovascular disease (CVD),4 and the majority of CKD patients die from
cardiovascular disease before reaching end-stage kidney disease.5-7 Furthermore, the risk for
CVD events increases rapidly as eGFR declines or albuminuria increases,8;9 independent of
other common risk factors such as diabetes or hypertension.10
The mechanisms of excess cardiovascular risk in CKD patients are not fully understood.
Predictive modeling using traditional cardiovascular risk factors performs poorly in this
patient group.11 Novel risk factors for cardiovascular disease, such as vascular calcification,
anemia, inflammation or increased oxidative stress may explain some of the excess risk in
advanced CKD,12-14 but they fail to fully explain the link between the two diseases.15;16
Recent genome-wide association studies (GWAS) of large European populations have
identified novel genetic risk single nucleotide polymorphisms (SNPs) for hypertension,17
coronary artery disease,18 subclinical vascular disease 19-22 as well as kidney functional
traits and CKD.23-25 We hypothesized that kidney variants might increase the risk of
vascular disease and that vascular variants might be similarly associated with kidney disease
traits. We tested this hypothesis by conducting bidirectional cross-trait targeted SNP
analyses between variants of eGFR, albuminuria and CVD and well-defined clinical
cardiovascular and kidney outcomes. In the first of two targeted SNP analyses, we selected
19 SNPs known to be associated with kidney function 23-25 and investigated their
association with the vascular phenotypes of systolic and diastolic blood pressure from the
ICBP17 (International Consortium for Blood Pressure) and coronary artery disease from the
CARDIoGRAM (Coronary Artery Disease Genome-wide Replication and Meta-Analysis)
consortium.18 We also analyzed the association of known kidney SNPs with well-defined
subclinical disease phenotypes, including: carotid-femoral pulse wave velocity from the
AortaGen consortium,20 retinal venular caliber from the CHARGE (Cohorts for Heart and
Aging Research in Genomic Epidemiology) Eye consortium,21 carotid intima-media
thickness (cIMT) from the CHARGE IMT consortium,19 and white matter lesions from the
NeuroCHARGE consortium.22 In the second targeted SNP analysis, 64 validated vascular
SNPs from a range of cardiovascular phenotypes were tested in eGFR and albuminuria
datasets from the CKDGen consortium.23-25
METHODS
Overall Study Design
For all phenotypes, testing for genetic association was performed using existing GWAS
meta-analysis datasets in individuals of European descent with self-reported ethnicity.
Genetic association testing for the kidney outcomes of eGFR and albuminuria was
performed in the CKDGen cohorts using existing meta-analysis results.23;24 Similarly,
association tests for vascular outcomes were conducted in most recent meta-analysis results
from the AortaGen,20 CARDIoGRAM,18 CHARGE Eye,21 CHARGE IMT,19 ICBP,17 and
NeuroCHARGE22 consortia. Heterogeneity tests were conducted in all consortia17-24 (e.g.
using Cochran's Q test in CKDGen).
Study Exposure
In the first targeted SNP analysis, we selected 18 kidney SNPs previously identified by
CKDGen in two-stage meta-analysis in association with creatinine-based eGFR (eGFRcr)
(15 loci), cystatin-C based eGFR (eGFRcys) (37 loci: CST3 [cystatin C] and SH2B3 [SH2B
adaptor protein 3])23 and albuminuria (1 locus, CUBN [cubulin]),24 as well as one SNP
yielded by IBC (Institute of Translational Medicine and Therapeutics Broad CARe)
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candidate-gene SNP association analyses in African Americans from the CARe Renal
Consortium (1 locus, KCNQ1 [kidney and cardiac voltage dependent K+ channel).25 The 19
kidney SNPs were tested for association with GWAS results for systolic and diastolic blood
pressure from ICBP (n=69,395), coronary artery disease from CARDIoGRAM (n=86,995
with 52,120 cases), as well as with markers of atherosclerosis: aortic pulse wave velocity
from AortaGen (n=20,634), retinal venular caliber from CHARGE Eye (n=15,358), cIMT
from CHARGE IMT (n=31,181) and brain white matter lesions from NeuroCHARGE
(n=12,385) consortia.
For the second targeted SNP analysis, 64 variants associated with blood pressure (29 loci in
ICBP), coronary artery disease (25 loci in CARDIoGRAM) or atherosclerosis (1 locus for
pulse-wave velocity in AortaGen, 4 loci with retinal venular caliber in CHARGE Eye, 3 loci
associated with cIMT in CHARGE IMT and 2 loci with white matter lesions in
NeuroCHARGE) were tested for association with two different estimations of GFR
(n=67,093 for eGFRcr and n=20,966 for eGFRcys) and albuminuria (n=31,580) in the
CKDGen consortium.
Kidney Measures
eGFRcr was estimated using the 4-variable Modification of Diet in Renal Disease Study
equation.26 eGFRcys was estimated as eGFRcys = 76.7 × (serum cystatin C)–1.19.27 CKD was
defined as eGFRcr < 60 ml / min /1.73 m2, according to National Kidney Foundation
guidelines.28 Urinary albumin-creatinine ratio (UACR) was log-transformed for analysis and
age and sex specific residuals were determined, as previously described.24 Albuminuria was
defined as UACR >17 mg/g for men and >25 mg/g for women.29
Vascular Measures
Hypertension was defined in ICBP consortium as systolic blood pressure ≥ 140mmHg or
diastolic blood pressure ≥ 90 mmHg.17 Coronary artery disease was defined in the
CARDIoGRAM consortium as symptoms of angina pectoris, previous myocardial infarction
or prior cardiac intervention.18 cIMT was measured in the CHARGE IMT consortium in the
common carotid artery as the distance between the lumen-intima interface and media-
adventitia interface by means of ultrasonography.19 The carotid-femoral pulse wave velocity
was assessed by AortaGen using carotid-femoral transit time assessed by tonometry or
Doppler flow and transit distance assessed by body surface measurements.20 The retinal
venular caliber was measured in CHARGE Eye using in-vivo imaging techniques.21 White
matter lesions were detected in NeuroCHARGE by means of magnetic resonance imaging.22
Statistical Methods
For the targeted SNP analyses, we used previously published results of meta-analyses of
HapMap [International HapMap Project]-imputed SNPs to test 19 kidney SNPs for
association with vascular traits and 64 cardiovascular SNPs in kidney traits. For the targeted
SNP analysis of 19 eGFR SNPs in 7 different vascular outcomes (blood pressure, coronary
artery disease, cIMT, aortic pulse-wave velocity, retinal venular caliber and white matter
lesions) we performed 133 tests. Similarly, for the targeted SNP analysis of 64 vascular
SNPs in 3 kidney-related outcomes (eGFRcr, eGFRcys and UACR), we performed 192 tests.
We adjusted for multiple testing using a Bonferroni corrected alpha of 1.5e-4 (0.05/325),
adjusting for all tests performed (133 + 192).
For each SNP, the results of the targeted meta-analysis included the effect estimator β, its
standard error, a two-sided p-value, as well as coded and non-coded allele, frequency of the
coded allele and the total sample size. Whenever the requested (lead) SNP was not available,
a proxy SNP with an r2 correlation of over 80% was used. In 4 cases, this was not possible,
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therefore 3 SNPs are missing from the analysis for coronary artery disease and 1 locus is
absent in all kidney analyses. Meta-analysis results corrected for genomic control were used
for all targeted analyses.
RESULTS
Study Participants
All study participants were of European descent. Study sample characteristics can be found
in Table 1. Details on the individual cohorts included are available in the original papers
that reported findings for eGFR,23;25 albuminuria,24 blood pressure,17 coronary artery
disease,18 cIMT,19 aortic pulse wave velocity,20 retinal venular caliber21 and white matter
lesions.22
Analysis of Validated Kidney SNPs in Vascular Traits
Association of kidney SNP variants with blood pressure—Results of associations
of kidney SNP variants with blood pressure in the ICBP consortium are presented in Table
2. In general, the variants tested were not associated with blood pressure at α=1.5e-4
(0.05/325) (p-value range, 0.98-0.002). The one exception was rs (reference SNP identifier)
653178 at the SH2B3 gene: each copy of the eGFR risk allele C (lower levels of eGFR) was
associated with a higher level of systolic (p=9.3E-10) and diastolic blood pressure
(p=1.6E-14). This SNP is in perfect linkage disequilibrium with rs3184504 (r2=1.0), which
has been previously reported in association with blood pressure.17
Association of kidney SNP variants with coronary artery disease—Results of
associations of kidney SNP variants with coronary artery disease in the CARDIoGRAM
consortium are presented in Table 2. The majority of tests were negative at α=1.5e-4, with
p-values ranging from 0.96 to 0.004. The one exception was rs653178 in the SH2B3 gene,
whose risk allele C was associated with a higher risk for coronary artery disease (odds ratio
[OR], 1.08; 95% confidence interval [CI], 1.04-1.11; p=2.2E-6). This SNP has been
previously reported by CKDGen in association with cystatin C-based eGFR (eGFRcys).18
Association of kidney SNP variants with subclinical markers of
atherosclerosis—The results of the association between kidney SNPs and cIMT, pulse
wave velocity, retinal venular caliber and white matter lesions are presented in Table 3.
Similar to what we observed for blood pressure and coronary artery disease, these variants
were not associated with these phenotypes at α=1.5e-4 (p-value range, 0.99-0.001), with the
exception of rs653178 near SH2B3, which was associated with high levels of retinal venular
caliber (p=2.9E-11). This SNP is in high linkage disequilibrium (r2=0.96) with another SNP
(rs10774625) in the same locus, previously reported by NeuroCHARGE in association with
retinal venular caliber.21
Analysis of Validated Vascular SNPs in Kidney Traits
Association of blood pressure variants with kidney traits—Association tests of 29
known blood pressure SNPs with eGFR and albuminuria (UACR) in the CKDGen
consortium are presented in Table 4. We observed one significant association with low
eGFR at α=1.5e-4: rs3184504 at the SH2B3 locus (p=1.06E-07). This SNP is perfectly
correlated with rs653178 (r2=1.0), which has been previously reported by CKDGen in
association with eGFRcys.23 All other association tests for eGFR and albuminuria were not
statistically significant (p-value range, 0.9-0.001).
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Association of coronary artery disease variants with kidney traits—Association
tests of 25 coronary artery disease variants with kidney traits in the CKDGen consortium are
presented in Table 5. In general, they did not associate with either eGFR or albuminuria at
α=1.5e-4 (0.05/325), with p-values ranging from 0.9 to 0.002. The exception was rs3184504
at SH2B3, whose risk allele T for coronary artery disease was associated with lower levels
of eGFR.
Association of subclinical cardiovascular SNP variants with kidney traits—The
association results for 10 known subclinical vascular SNP variants (3 loci for cIMT, 1 locus
for pulse-wave velocity, 4 loci for retinal venular caliber and 2 loci for white matter lesions)
with kidney traits in the CKDGen consortium are reported in Table 6. The majority of tests
were not significant at α=1.5e-4 (p-value range, 0.9-0.0005), with the exception of
rs10774625 at SH2B3, which was associated with lower levels of eGFR (p=7.05E-08). This
SNP was previously noted in association with retinal venular caliber21 and is in strong
linkage disequilibrium (r2=0.96) with the other 2 SNPs in the same locus, which have
previously been reported.17;18;23
Concordance Between Vascular SNP Variants and eGFR
In the CKDGen Consortium, only 96 of 189 CVD risk variants tested were in the expected
direction, (i.e. were associated with lower eGFR) whereas 93 were in the opposite direction
(p=0.9) (Fig. 1). Similar patterns of discordance were observed in all vascular consortia,
where only 70 out of 127 tested variants showed association in the hypothesized direction
(p=0.3).
DISCUSSION
We observed minimal overlap in genetic association of well-validated SNPs across a variety
of kidney and vascular traits. The exception was SH2B3, which has previously been
reported as associated with several traits. The absence of association observed suggests that
there is little overlap between kidney disease and CVD risk variants.
The general lack of association seen in our analyses is consistent with recent findings of the
ICBP consortium, where investigators constructed a genetic risk score for the 29 SNPs
related to blood pressure and found evidence of genetic overlap with left ventricular wall
thickness, incident heart failure, stroke and coronary artery disease, but not with kidney
disease or kidney function.17 Our study advances our understanding in this area, by
demonstrating a similar lack of a shared genetic basis to a broad range of well-characterized
cardiovascular and kidney traits.
The SH2B3 locus is the one exception to these negative results, demonstrating robust and
direction-consistent associations with increased blood pressure, higher OR for coronary
artery disease and increased retinal venular caliber as opposed to lower levels of eGFR in
the general population. Located at 12q24, SH2B3 encodes a member of the SH2B adaptor
family of proteins, which play a role in signal, hematopoiesis, and immune response
activities by integrin, growth factors and cytokines.24;30;31 The reason for the joint
associations between these variants may be due to pleiotropic effects of this gene. The
SH2B3 region is recognized for pleiotropy, associating with multiple phenotypes including
platelet count,32 susceptibility to insulin-dependent diabetes mellitus33 and celiac disease
type 13.34 A recent attempt to measure pleiotropic effects for known kidney and vascular
loci demonstrated SH2B3 to have the highest pleiotropic index among all other identified
regions.35
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Several avenues for future research are suggested by the present analysis, which may
improve our understanding of the mechanism of vascular disease in kidney patients, help
stratify CKD patients by their risk of developing vascular disease or potentially identify
novel pharmacogenomics targets. In particular, studies targeted at achieving a better
understanding of the role of SH2B3 in both kidney disease and CVD may prove fruitful. For
example, the observation that SH2B3 is strongly associated with cystatin-C-based eGFR but
only nominally so with creatinine-based eGFR, suggests that its effects on GFR may be
indirect, perhaps mediated by influences on cystatin C production or metabolism, which is a
better predictor of CVD than eGFRcr.36 This is supported by the fact that SH2B3 showed no
association to urinary ACR due to distinct genetic mechanisms of eGFR and albuminuria, in
accordance with a prior interrogation which found a lack of association between CKD-
related SNPs and albuminuria.37 Furthermore, as the SH2B3 gene region is large (45,674
nucleotides, based on Ensembl gene annotation release 54) and includes several other genes,
fine-mapping studies may identify the causal variant(s) underlying the statistical signals
identified in this and other analyses.
The absence of cross-associations does not necessarily imply absence of genetic correlation
and there may be other contributing mechanisms to explain these findings. For example, in
totality, the previously identified kidney function loci only account for 1.4% of the variation
of eGFR,23 with similar values reported by ICBP for the association with blood pressure17
and CARDIoGRAM for coronary artery disease.18 The relatively low explained variance of
trait variation may account for the lack of overlap in these analyses, and it remains possible
that shared variants may yet be identified as a greater proportion of the underlying genetic
variability is explained. However, the ICBP study demonstrated that even SNPs in low
linkage disequilibrium can identify overlapping associations with downstream traits,17
supporting our negative findings.
Our findings suggest that non-genetic or environmental factors are primarily responsible for
the association between CKD and CVD, either via a direct causal link or by lying in the
causal pathway. Examples of such factors include uremic toxins not cleared by the failing
kidney, vascular calcification, anemia, inflammation or increased oxidative stress account,
which have a higher prevalence in CKD patients as compared to the overall population.12-14
For example, indoxyl sulfate is a uremic toxin that accelerates vascular disease in CKD
patients via AHR (aryl hydrocarbon receptor) and other pathways, but which is not relevant
to CVD in the overall population.38 Such environmental mechanisms would not be
detectable by the present approach. The lack of genetic association between kidney disease
and CVD emphasizes the influence of shared risk factors in the CKD-CVD milieu,
particularly diabetes and hypertension.
Strengths of this study include the largest to date available GWAS datasets for kidney traits,
blood pressure, coronary artery disease and subclinical vascular markers from the CKDGen,
ICBP, CARDIoGRAM, CHARGE Eye, CHARGE IMT, NeuroCHARGE and AortaGen
consortia, as well as the use of validated SNP variants for these traits. Some limitations also
warrant mention. First, as genetic variations for eGFR, albuminuria and CVD explain only
about 1% of the variations of these traits, the combined effect size of the SNPs for eGFR
and vascular outcomes may be too low to detect shared genetic associations. Second,
whereas our study indicates little overlap in the common genetic determinants of CKD and
CVD, similar analyses in cohorts targeted at more advanced stages of CKD or containing
more cases of both diseases may yield different findings. Third, our study used common
genetic variants derived from GWAS and it is therefore possible that low frequency variants
could provide more evidence for joint association. Furthermore, future GWAS, exome
sequencing or pathway analyses may yet reveal shared genetic underpinnings between these
Olden et al. Page 7
Am J Kidney Dis. Author manuscript; available in PMC 2014 June 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
traits. Finally, our study sample was composed of individuals of European ancestry;
therefore the generalizability of our findings across other ethnic groups is uncertain.
In conclusion, we observed overall little genetic overlap between well-validated SNPs for
kidney disease and CVD and their related phenotypes in targeted SNP analyses conducted in
largest to date available meta-analyses results. Although we confirm one locus, SH2B3,
which is associated with both kidney disease and CVD, our primary findings suggest that
there is little overlap between kidney disease and CVD risk variants. The interrelationship
between these traits may thus be primarily due to clinical factors present in the setting of
CKD or CVD.
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Figure 1.
Scatter plot of SNP effect sizes (beta) for creatinine-based eGFR (eGFRcr) and vascular
phenotypes (systolic blood pressure [filled diamonds], carotid-intima medial thickness
[filled triangles], pulse-wave velocity [×], retinal venular caliber [filled squares], and white
matter lesions [filled circles]. The side labeled A (lower eGFRcr effect size, higher vascular
effect size) represents associations consistent with the study hypothesis; the side labeled B
(higher eGFRcr effect size, higher vascular effect size) represents associations inconsistent
with the hypothesis. The results show no significant correlation between eGFRcr and
vascular SNP variants.
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; c
IM
T,
 c
ar
ot
id
 in
tim
a-
m
ed
ia
 th
ic
kn
es
s; 
PW
V
, p
ul
se
-w
av
e 
ve
lo
ci
ty
; R
V
C,
 re
tin
al
 v
en
ul
ar
 c
al
ib
er
; W
M
L,
 w
hi
te
 m
at
te
r l
es
io
n;
 S
N
P,
 si
ng
le
 n
uc
le
ot
id
e 
po
ly
m
or
ph
ism
*
Si
gn
ifi
ca
nt
 a
ss
oc
ia
tio
ns
 a
fte
r B
on
fe
rro
ni
 c
or
re
ct
io
n 
fo
r m
ul
tip
le
 te
sti
ng
 (p
 ≤ 
1.5
e-4
).
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